Warming Up the Cold: A New Hope for Immunotherapy in Prostate Cancer
Recent research, however, identifies a key reason: SPP1+ macrophages and adenosine signaling, both of which shield cancer cells from immune response. A new drug, ciforadenant, blocks adenosine’s effects, reactivating immune cells.
Recent research, however, identifies a key reason: SPP1+ macrophages and adenosine signaling, both of which shield cancer cells from immune response. A new drug, ciforadenant, blocks adenosine’s effects, reactivating immune cells.